AstraZeneca commences Ph III trials of AZD1222

Aug 31, 2020

AstraZeneca announced it has commenced Ph III trials of AZD1222. Up to 30,000 adults in the US will be recruited, with testing sites also in Peru, Chile, UK, Brazil and South Africa. The results of the trial are anticipated later this year.

Print Page Mail Article